% | $
Quotes you view appear here for quick access.

Advanced Medical Isotope Corporation Message Board

  • Apr 29, 2013 2:42 PM Flag

    Darwinian Selection In Medical Devices: Brachytherapy Offers Investors Hope

    I believe RadioGel is a pioneering technology in the brachytherapy sector because it holds marked clinical advantages over traditional implants. Specifically, RadioGel's list of clinical advantages include but are not limited to the following:

    - Yttrium-90 has a half-life of only 2.7 days

    - Yttrium-90 has considerably clinical evidence showing efficacy against inoperable liver tumors

    - Ytrrium-90 has shown promise in reducing tumors in a variety of cancer types

    - Yttrium- 90 is a beta-emitter, making it safer for clinicians and patients alike

    - No metal casings to deal with

    - Gel is biodegradable and can thus be easily reabsorbed by the body

    - Gel forms a solid lattice that holds the Yttrium-90 in place and is thermally reversible

    To put this into context, I believe that patients given a choice between a surgically implanted medical casing with a long-lived isotope such as iridium-192 or a gel that dissolves in a few days, the patient is going to choose RadioGel every time. Given that the clinical research thus far is painting a promising picture for yttrium-90 in a diverse array of cancers, I believe RadioGel has a strong chance to become the standard of care in brachytherapy procedures. Unfortunately, I wasn't able to get an estimate on the timeframe for FDA review of RadioGel, but instead was informed by the agency that they cannot currently comment on a device that is "under-review". Based on historical precedence, however, I think RadioGel could be approved before the end of 2013.

    Sentiment: Strong Buy

0.00140.0000(0.00%)Nov 27 12:47 PMEST